[Ip-health] Ranbaxy debacle: Big Pharma’s target is Indian drug industry

Gopa Kumar kumargopakm at gmail.com
Thu May 30 05:38:26 PDT 2013


Ranbaxy debacle: Big Pharma’s target is Indian drug industry

*by  <http://www.firstpost.com/author/>*May 30, 2013

#big pharma <http://www.firstpost.com/tag/big-pharma>
#Drugs<http://www.firstpost.com/tag/drugs>
 #Healthcare <http://www.firstpost.com/tag/healthcare>
#India<http://www.firstpost.com/tag/india>
 #Medicines <http://www.firstpost.com/tag/medicines>
#Ranbaxy<http://www.firstpost.com/tag/ranbaxy>
Email <http://www.addthis.com/bookmark.php>Print<http://www.firstpost.com/printpage.php?idno=827071&sr_no=0>
Share <http://www.firstpost.com/printpage.php?idno=827071&sr_no=0#>
inShare <http://www.firstpost.com/printpage.php?idno=827071&sr_no=0>Comments<http://www.firstpost.com/business/ranbaxy-debacle-big-pharmas-target-is-indian-drug-industry-827071.html#disqus_thread>

It's abundantly clear that the Ranbaxy fiasco in the US, in which the
company has to pay $500 million for allegedly selling adulterated drugs, is
the big opportunity that the multinational drug companies have been waiting
for to malign India.

Grabbing Ranbaxy by the scruff of its neck, the propaganda machines of the
Big Pharma have unleashed a campaign against Indian generic manufacturers:
if India's $2 billion dollar Ranbaxy is bad, the rest of the industry
should be bad as well. Their medicines are dirty and they are really bad
not just for the North Americans and Europeans, but for Africans and Latin
Americans as well.

The glee of Fortune magazine, which has been editorially campaigning for
quite a while against the generic drugs and Indian patent regime alleging
that they compromise on quality and safety of people, was effusive. The
title of its widely circulated story on the Ranbaxy case was the message by
itself: Dirty Medicine<http://features.blogs.fortune.cnn.com/2013/05/15/ranbaxy-fraud-lipitor/>
.

*It was not just about Ranbaxy, but also about India and its “dirty”
generics.*

The Fortune story leads with an Indian protagonist, Dinesh Thakur, a former
Bristol-Myers Squibb employee who joined Ranbaxy only to turn a
whistleblower. Over a few years, he successfully got Ranbaxy penalised and
pocketed a neat $49 million for his inside job. Along with the MNC
propagandists, Thakur also continues his anti-generics campaign
<http://dineshthakur.com/>which
is willy-nilly aimed at the Indian generic industry.

Thakur's role in exposing the “fraud” and the Ranbaxy story are now public
knowledge, but the Fortune article has an innocuous mention of how his
three-year-old son's ear infection that a Ranbaxy antibiotic didn't cure
was cleared only by a GlaxoSmithKline drug. “Now he took the boy in his
arms and resolved not to give his family any more Ranbaxy drugs until he
knew the truth,” the article says to drive home the fear factor on Indian
drugs.

For Big Pharma propaganda, Ranbaxy is just the symbol. The rest of the
story is about what is projected as the big, dark, deceitful and dirty
world of the Indian drug industry. They repeat the same message over and
over again: generics, particularly made in dirty Indian labs through
deceitful ways, are not as good as the original branded drugs; and they
compromise Americans' health and safety.

][image: Grabbing Ranbaxy by the scruff of its neck, the propaganda
machines of the Big Pharma have unleashed a campaign against Indian generic
manufacturers. Getty Images]Grabbing Ranbaxy by the scruff of its neck, the
propaganda machines of the Big Pharma have unleashed a campaign against
Indian generic manufacturers. Getty Images
It reinforces the public perception that the Big Pharma media campaigns
have been able to sustain: a Pew survey in 2010 showed that 50 percent of
Americans distrusted Indian drugs and 70 percent, Chinese drugs.

The language is in fact lethal, and the purpose sinister.

“Pharmaceutical companies in developing countries such as India are
increasingly exporting potentially dangerous low-cost, off-patent drugs
overseas. Some of these lethal products have even slipped past US Food and
Drug Administration regulations,” said an American Enterprise Institute
article early this year.  In January, the Fortune magazine asked: Are
generics really the same as branded drugs?
<http://management.fortune.cnn.com/2013/01/10/generic-drugs-quality/>

*What is the real truth?*

Let's pose the same questions to the US Food and Drug Administration
(FDA)<http://www.fda.gov/Drugs/ResourcesForYou/Consumers/QuestionsAnswers/ucm100100.htm>
.

It has a diametrically opposite view.

“Yes. A generic drug is the same as a brand-name drug in dosage, safety,
strength, quality, the way it works, the way it is taken and the way it
should be used.”

*Are they safe?*

“Health care professionals and consumers can be assured that FDA approved
generic drug products have met the same rigid standards as the innovator
drug. All generic drugs approved by FDA have the same high quality,
strength, purity and stability as brand-name drugs. And, the generic
manufacturing, packaging, and testing sites must pass the same quality
standards as those of brand name drugs.”

This is exactly the reason for the heartburn of the multinational drug
companies that are looking for opportunities such as the Ranbaxy debacle
for their propaganda. America cannot survive without the generic drugs. In
fact, 80 percent of the prescriptions in the US are met by generics, a lot
of them Indian. Doctors and hospitals have been using them for several
decades.

It saves the country and its people lot of money too. As the FDA itself
notes, “according to the Congressional Budget Office, generic drugs save
consumers an estimated $8 to $10 billion a year at retail pharmacies. Even
more billions are saved when hospitals use generics.”

While the Big Pharma raise the bogey of dirty drugs and lack of safety, FDA
has engaged its own staff and resources to tell people that the stories of
lack of safety they hear are wrong. It quotes one of its senior
pharmacists: "every day without fail we educate consumers and health care
professionals about the safety and efficacy of generic drugs. It even
released PSAs to tell people the same.

*Now, let's briefly look at the Ranbaxy case itself.*

By volunteering to pay a hefty amount, the company would have had some
reason to feel vulnerable and guilty. They wouldn't have wanted to
jeopardise their chances in the US because US generic market is lucrative,
particularly in the first six months after the expiry of a patent when a
drug company with a first-mover advantage can make a lot of money before
others also get an opportunity.

However, the only FDA-charge against the company was that it “falsified
drug data and systemically violated current good manufacturing practices
and good laboratory practices."

Isn't that serious enough?

Yes, indeed.

But it doesn't tell the complete story.

This is only the last of the seven conditions that the FDA has laid down
for allowing generics into the US market. The federal agency or the
anti-generic campaigners haven't said that Ranbaxy has failed the most
important conditions such as the same active ingredients as the innovator
drug, being identical in strength, same dosage form and route of
administration; same use indications; same bioequivalence; and same batch
requirements for identity, strength, purity and quality.

DG Shah, Secretary General of the Indian Pharmaceutical Alliance (IPA), has
no doubts that the efforts are to malign Indian pharmaceutical industry.
Both the big pharma companies as well as the western generic manufacturers
are behind this campaign.

*Will it impact Indian exports? *

Shah feels that there would be no immediate impact because Indian generic
drugs have been in use in the US for years. India's record with the FDA has
been consistently good and they have been very appreciative of the Indian
drugs. The Ranbaxy episode might lead to sharper probing and scrutiny,
which will anyway be good for the Indian industry.

According to the IPA, almost 55 percent of the revenue of the Indian
generics - which is about $13 billion - comes from overseas markets. Of
this, 50 percent are from regulated markets of North America, Japan and
Europe and the rest are from 225 middle and low-income countries. In other
words, if exports are hit, the industry will be seriously hurt.

Given the low awareness and educational levels, the campaign against India,
however, might have some impact in Latin America and Africa, which accounts
for about 21 percent of the export earnings. As was seen in the
AIDS-epidemic, India is the pharmacy of the poor countries of the world, a
fact that peeves both the Big Pharma and western generic manufacturers.

While resisting its intent, the Ranbaxy case and the campaign to discredit
India should be turned into an opportunity. It should be treated as a
wake-up call to ensure complete adherence to manufacturing and
certification of best practices and total quality. The Big Pharma is out to
get the generic industry, particularly in India.

They use every opportunity to conflate lower standards and denial of
patents with counterfeit drugs. The Americans are also trying to use the UN
agency for drug and crime (UNODC) to take up the issue of counterfeits in
its multipronged strategy to discredit drug industries in countries such as
India.

Indian drug industry should mend its ways, not just for the overseas
market, but also for its own citizens because generics are the only
lifeline for millions of Indians. For the Americans, they have an extremely
meticulous FDA; but for Indians?

Any behavior that endangers their lives should be considered criminal.
http://www.firstpost.com/business/ranbaxy-debacle-big-pharmas-target-is-indian-drug-industry-827071.html



More information about the Ip-health mailing list